Clinical trials: Cellular Therapy
Parkinson Disease
Phase 1/2a Study of ANPD001 in Parkinson Disease
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease.
- Trial name
- ASPIRO (NCT06344026)
- Testing
- ANPD001, Custom Device
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Aspen Neuroscience
Diffuse Large B-cell Lymphoma
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity.
- Trial name
- DLBCL (NCT01186978)
- Testing
- Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Parkinson's Disease
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also…
- Trial name
- STAR (NCT06683378)
- Testing
- Reparative Autologous peripheral nerve tissue
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Craig van Horne, MD, PhD
Non-Small Cell Lung Cancer
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
This 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients with locally advanced or metastatic non-small cell…
- Trial name
- NCT00718315
- Testing
- erlotinib [Tarceva], fusidic acid [Verutex], erythromycin [Eritex]
- Where
- 26 sites in Brazil
- Volunteers
- 201 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant toripalimab combined with chemotherapy and low-dose radiotherapy in patients with esophageal squamous cell carcinoma who are insensitive to…
- Trial name
- NCT07272291
- Testing
- Toripalimab
- Volunteers
- 48 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Adenocarcinoma, Stage I, Diagnoses Diseases
Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma
In 2015-2016, 224,390 cases were newly diagnosed with lung cancer in USA. Of all the cases, 83% are non-small cell lung cancer (NSCLC).
- Conditions
- Lung Adenocarcinoma, Stage I, Diagnoses Diseases, Circulating Tumor Cells, Treatment
- Trial name
- CTCs detection (NCT02951897)
- Testing
- lobectomy, segmentecomy, chemotherapy（pemetrexed+CISPLATIN）
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Third Military Medical University
Non-small Cell Lung Cancer
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
This is a multicenter, single-arm phase II clinical study to evaluate the safety and efficacy of pyrotinib maleate as a first-line treatment for HER2-mutated or amplified non-small cell lung cancer.
- Trial name
- NCT05751018
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking Union Medical College Hospital
Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
This is a phase 2, open label, single arm trial. This study aims to assess the efficacy and safety of menin inhibitor BN104 as maintenance therapy in patients with acute leukemia harboring specific genetic alterations who have…
- Conditions
- Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy, Acute Leukemia
- Trial name
- NCT07101497
- Testing
- BN104 monotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
B-cell Lymphoma Refractory
Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas
The purpose of this study is to evaluate progression free survival, transplant-related morbidity (TRM) at day +100 and at +365, overall survival and incidence of acute and chronic GVHD in refractory/early relapsed aggressive…
- Trial name
- TBF (NCT01786018)
- Testing
- Thiotepa, Busulfan, Fludarabin
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia
Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment
The study aims to evaluate the occurrence, mortality, and risk factors for invasive mold infections (IMI) in children treated with chemotherapy for acute leukemia in Denmark.
- Trial name
- NCT05774990
- Where
- Denmark
- Volunteers
- 621 people
- Sponsor
- University of Southern Denmark
Non Small Cell Lung Cancer
Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.
This is an observational study to evaluate the feasibility of the implementation of a personalized treatment strategy based on specific tumor marker (f.i.
- Trial name
- HERMES (NCT01260038)
- Where
- 11 sites in Belgium
- Volunteers
- 107 people
- Sponsor
- University Hospital, Antwerp
Resectable Non-Small-Cell Lung Cancer
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
This study aims to explore the efficacy and safety of thymosin α-1 (Tα1) plus chemotherapy and PD-1 inhibitors as neoadjuvant therapy for operable non-small cell lung cancer
- Trial name
- NCT06607926
- Testing
- Thymosin Alpha 1, Tislelizumab, Platinum-doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xuanwu Hospital, Beijing
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Hematologic Malignancy
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation
The LLLT has an anti-inflammatory, analgesic effect and accelerates the healing of ulcerated lesions. There are little data in the literature showing its efficacy in prevention of mucositis in cohorts of patients with…
- Trial name
- STOP MUCITES (NCT02696408)
- Testing
- Laser treatment
- Where
- 3 sites in France
- Volunteers
- 234 people
- Sponsor
- Institut de Cancérologie de la Loire
Melanoma
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic…
- Trial name
- NCT00107718
- Testing
- SB-485232
- Where
- 20 sites in United States, Australia
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
CLEAR CAR-T cell injection (ET-970) is an engineered CD70-targeting allogeneic Chimeric Antigen Receptor T-Cell (CAR-T cell). This is a multi-center, single-arm, open-label, early exploratory clinical study.
- Trial name
- NCT07645690
- Testing
- CLEAR CAR-T cell injection
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Neuroblastoma
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or by killing them. It also prepares the patient's bone marrow for the stem cell transplant.
- Trial name
- NCT00526318
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 68 sites in Germany, Switzerland
- Volunteers
- 360 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
Background: Small-cell lung cancer (SCLC) is the most deadly form of lung cancer. It kills at least 250,000 worldwide each year.
- Conditions
- Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
- Trial name
- NCT07328490
- Testing
- Tarlatamab, Sacituzumab Govitecan
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Executive Functioning, Pediatric ALL
Effectiveness of EEG Neurofeedback in Pediatric Occupational Therapy to Improve Executive Functioning
EEG Neurofeedback is a noninvasive way that allows the central nervous system to self regulate and the frontal cortex to be accessed through quieting of the limbic system at the subcortical level.
- Trial name
- NCT04221620
- Testing
- Zengar Electroencephalogram (EEG) Neurofeedback device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northern Arizona University
Resectable Head and Neck Squamous Cell Carcinoma
Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to evaluate the anti-tumor activity, safety and tolerability of the combination of Sacituzumab govitecan and Tagitanlimab as neoadjuvant therapy in patients with resectable head and neck…
- Trial name
- NCT07492914
- Testing
- Sacituzumab Govitecan, Tagitanlimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- West China Hospital